News Related to Alcoholic Liver Disease

Related coverage linked through entity extraction aliases.

GSK Licenses Linerixibat to Alfasigma for $690M; Eisai's E2086 Receives Orphan Designation

Mar 09, 2026

GSK agreed to license linerixibat to Alfasigma in a deal worth up to $690 million, while Eisai received orphan drug designation in Japan for E2086, a novel selective orexin 2 receptor agonist for narcolepsy.

SGLT2 Inhibitors, GLP-1 RAs Show Cardiorenal and Hepatic Benefits in Type 2 Diabetes

Mar 03, 2026

New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.